Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 161

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 161
---
 balance of which would be payable no later than 90 days after the signing of the License Agreement, with either Aadi or WuXi Biologics
having the right to extend the latter deadline by an additional 30 days; and (iii) provided that the License Agreement would automatically terminate if the balance of the upfront license fee payment was not paid by the applicable deadline.
Following the delivery of such draft, representatives of Aadi and WuXi Biologics continued to share drafts of and negotiate the License Agreement until its signing on December 19, 2024.

On December 6, 2024, Aadi’s board of directors held a virtual meeting with Aadi’s management and representatives of Wilson Sonsini. At the
meeting, Aadi’s management team provided an update regarding the status of the License Agreement and related transactions and discussed, among other things, the proposed non-refundable payment of
$6.0 million due upon signing the License Agreement. Aadi’s management team also

- 104 -

provided an update regarding the PIPE Financing, including a process summary and a report of investor demand to date resulting from 30 one-on-one meetings with prospective investors, several of whom declined to participate due to concerns regarding the expected pricing of the PIPE Financing or the preclinical stage of the

ADC Programs, among other factors. Aadi’s board of directors deliberated regarding the foregoing matters and also discussed with the management team,
among other things, the anticipated timing, price and size of the PIPE Financing and investor feedback to date regarding the ADC Programs, including those declining to participate in the PIPE Financing. Further, Aadi’s board of directors
discussed the formation of a PIPE Pricing Committee, which would consist of the disinterested directors of Aadi’s board of directors with respect to License Agreement and the PIPE Financing, as well as Aadi’s engagement letter with
Jefferies. Following discussion, Aadi’s board of directors (i) formed the PIPE Pricing Committee, effective immediately, comprised of disinterested directors Neil Desai, Ph.D., Karin Hehenberger, M.D., Ph.D., Mohammad Hirmand, M.D.,
Richard Maroun and Emma Reeve, and (ii) ratified the Jefferies engagement letter. As established by Aadi’s board of directors, the PIPE Pricing Committee had the full power and authority of Aadi’s board of directors to
(i) consider, explore, evaluate, assist in the oversight of, and make recommendations to Aadi’s board of directors regarding the PIPE